However, the addition of carbidopa enhanced the effects of topically applied levodopa, similar to that seen during its systemic use for the treatment of neurological disorders, by presumably inhibiting its premature break-down by the enzyme aromatic l-amino acid decarboxylase (AAAD)29, and thus lowering the dose of levodopa required to achieve protection. This evidence concerns the gene DDC and nervous system disorder.